Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.

Ampullary cancers refer to tumors originating from the ampulla of Vater (the ampulla, the intraduodenal portion of the bile duct, and the intraduodenal portion of the pancreatic duct), while periampullary cancers may arise from locations encompassing the head of the pancreas, distal bile duct, duodenum, or ampulla of Vater. Ampullary cancers are rare gastrointestinal malignancies, and prognosis varies greatly based on factors such as patient age, TNM classification, differentiation grade, and treatment modality received. Systemic therapy is used in all stages of ampullary cancer, including neoadjuvant therapy, adjuvant therapy, and first-line or subsequent-line therapy for locally advanced, metastatic, and recurrent disease. Radiation therapy may be used in localized ampullary cancer, sometimes in combination with chemotherapy, but there is no high-level evidence to support its utility. Select tumors may be treated surgically. This article describes NCCN recommendations regarding management of ampullary adenocarcinoma.

[1]  T. Seufferlein,et al.  Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Quality of life results of the randomized phase II AIO-NEONAX trial. , 2023, Journal of Clinical Oncology.

[2]  G. Abou-Alfa,et al.  55P Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal Irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC) , 2022, Annals of Oncology.

[3]  A. Saborowski,et al.  53MO Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC – AIO-HEP-0116) , 2022, Annals of Oncology.

[4]  A. Drilon,et al.  Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. , 2022, The Lancet. Oncology.

[5]  A. Singhi,et al.  Neoadjuvant Therapy Versus Upfront Resection for Nonpancreatic Periampullary Adenocarcinoma , 2022, Annals of Surgical Oncology.

[6]  J. Meyerhardt,et al.  Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. , 2022, JAMA oncology.

[7]  J. W. Kim,et al.  Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. , 2022, NEJM evidence.

[8]  Song-Cheol Kim,et al.  Controversial benefit of 5-fluorouracil/leucovorin-based adjuvant chemotherapy for ampullary cancer: a propensity score-matched analysis , 2022, Langenbeck's Archives of Surgery.

[9]  A. Sauvanet,et al.  The long-term outcomes of laparoscopic versus open pancreatoduodenectomy for ampullary carcinoma showed similar survival: a case-matched comparative study , 2021, Surgical Endoscopy.

[10]  K. Ichimura,et al.  The Impact of KRAS Mutation in Patients With Sporadic Nonampullary Duodenal Epithelial Tumors , 2021, Clinical and translational gastroenterology.

[11]  E. Van Cutsem,et al.  First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  T. Aoki,et al.  Efficacy and Feasibility of Adjuvant Gemcitabine Plus Cisplatin Chemotherapy After Major Hepatectomy for Biliary Tract Cancer , 2021, AntiCancer Research.

[13]  J. Berlin,et al.  Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513 , 2021, Clinical Cancer Research.

[14]  R. Shen,et al.  Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care , 2021, Clinical Cancer Research.

[15]  J. Hainsworth,et al.  Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. , 2021, The Lancet. Oncology.

[16]  D. Berton,et al.  Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: A combined analysis of two cohorts in the GARNET study. , 2021 .

[17]  W. Ryder,et al.  Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial , 2021, The Lancet. Oncology.

[18]  S. Bozzarelli,et al.  Long-term outcomes after pancreatoduodenectomy for ampullary cancer: The influence of the histological subtypes and comparison with the other periampullary neoplasms. , 2021, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[19]  C. V. van Eijck,et al.  Preoperative misdiagnosis of pancreatic and periampullary cancer in patients undergoing pancreatoduodenectomy: A multicentre retrospective cohort study. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[20]  N. Kumari,et al.  Identification of PI3K-AKT signaling as the dominant altered pathway in intestinal type ampullary cancers through whole-exome sequencing , 2021, Journal of pathology and translational medicine.

[21]  C. Dejong,et al.  A population-based study on incidence, treatment, and survival in ampullary cancer in the Netherlands. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[22]  A. Ejaz,et al.  Neoadjuvant therapy versus surgery first for ampullary carcinoma: A propensity score‐matched analysis of the NCDB , 2021, Journal of surgical oncology.

[23]  C. Strassburg,et al.  Improving quality of life in pancreatic cancer patients following high-intensity focused ultrasound (HIFU) in two European centers , 2021, European Radiology.

[24]  Namita S. Gandhi,et al.  Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. , 2021, JAMA oncology.

[25]  Rong Liu,et al.  Comment On "500 Minimally Invasive Robotic Pancreatoduodenectomies: One Decade of Optimizing Performance". , 2020, Annals of surgery.

[26]  N. Kumari,et al.  Prevalence and spectrum of pathogenic germline variants in intestinal and pancreatobiliary type of ampullary cancer. , 2020, Pathology, research and practice.

[27]  R. Greil,et al.  Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. , 2020, The Lancet. Oncology.

[28]  G. Williams,et al.  The Clinical Benefit of Adjuvant Therapy in Long-Term Survival of Early-Stage Ampullary Carcinoma: A Single Institutional Experience , 2020, Journal of clinical medicine research.

[29]  R. Gray,et al.  Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Yanming Zhou,et al.  Prognostic factors and benefits of adjuvant therapy for ampullary cancer following pancreatoduodenectomy: A systematic review and meta-analysis. , 2020, Asian journal of surgery.

[31]  G. Fontanini,et al.  Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. , 2020, The Lancet. Oncology.

[32]  M. Katz,et al.  Management of ampullary adenomas in familial adenomatous polyposis syndrome: 16 years of experience from a tertiary cancer center. , 2020, Gastrointestinal endoscopy.

[33]  A. Chen,et al.  Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Weitz,et al.  Adjuvant therapy is associated with improved overall survival in patients with pancreatobiliary or mixed subtype ampullary cancer after pancreatoduodenectomy - A multicenter cohort study. , 2020, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[35]  Lianchun Xiao,et al.  Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers , 2020, World journal of gastrointestinal oncology.

[36]  L. Diaz,et al.  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Drilon,et al.  Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.

[38]  S. Detlefsen,et al.  Mutational profiling and immunohistochemical analysis of a surgical series of ampullary carcinomas , 2019, Journal of Clinical Pathology.

[39]  Jae Hoon Lee,et al.  Laparoscopic pancreaticoduodenectomy for periampullary tumors: lessons learned from 500 consecutive patients in a single center , 2019, Surgical Endoscopy.

[40]  D. Adler,et al.  Demographics, tumor characteristics, treatment, and clinical outcomes of patients with ampullary cancer: a Surveillance, Epidemiology, and End Results (SEER) cohort study. , 2019, Minerva gastroenterologica e dietologica.

[41]  D. Morton,et al.  FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. , 2019, Journal of Clinical Oncology.

[42]  S. Kumer,et al.  Clinical Outcome of Ampullary Carcinoma: Single Cancer Center Experience , 2019, Journal of oncology.

[43]  Jin‐Young Jang,et al.  Recurrence patterns after pancreaticoduodenectomy for ampullary cancer , 2019, Journal of hepato-biliary-pancreatic sciences.

[44]  B. Taylor,et al.  Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes , 2019, Cancer.

[45]  P. Rabinovitch,et al.  Diagnosis, risk stratification, and management of ampullary dysplasia by DNA flow cytometric analysis of paraffin-embedded tissue , 2019, Modern Pathology.

[46]  J. Raftery,et al.  Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. , 2019, The Lancet. Oncology.

[47]  A. Barkun,et al.  Endoscopic Resection of Ampullary Tumours: Long-term Outcomes and Adverse Events , 2019, Journal of the Canadian Association of Gastroenterology.

[48]  Thierry Lecomte,et al.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer , 2018, The New England journal of medicine.

[49]  A. El Nakeeb,et al.  Predictors of long-term survival after pancreaticoduodenectomy for peri-ampullary adenocarcinoma: A retrospective study of 5-year survivors. , 2018, Hepatobiliary & pancreatic diseases international : HBPD INT.

[50]  Sung-Sik Han,et al.  Very early recurrence following pancreaticoduodenectomy in patients with ampullary cancer , 2019, Medicine.

[51]  M. Bruno,et al.  Endoscopic resection of advanced ampullary adenomas: a single-center 14-year retrospective cohort study , 2018, Surgical Endoscopy.

[52]  J. Wan,et al.  Ampullary adenocarcinoma: Defining predictors of survival and the impact of adjuvant therapy following surgical resection for stage I disease , 2018, Journal of Surgical Oncology.

[53]  D. Nagorney,et al.  Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[54]  M. Choti,et al.  Association of Adjuvant Therapy with Improved Survival in Ampullary Cancer: A National Cohort Study , 2018, Journal of Gastrointestinal Surgery.

[55]  M. Choti,et al.  Determining the Adequate Examined Lymph Node Count in Resected Ampullary Adenocarcinoma—A National Cohort Study , 2018, Journal of Gastrointestinal Surgery.

[56]  S. Kamarajah Adjuvant radiotherapy following pancreaticoduodenectomy for ampullary adenocarcinoma improves survival in node-positive patients: a propensity score analysis , 2018, Clinical and Translational Oncology.

[57]  Funda Meric-Bernstam,et al.  Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.

[58]  M. Sawyer,et al.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  R. Stupp,et al.  Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study , 2018, BMC Cancer.

[60]  J. Hainsworth,et al.  Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  P. Senthilnathan,et al.  Randomized clinical trial of laparoscopic versus open pancreatoduodenectomy for periampullary tumours , 2017, The British journal of surgery.

[62]  M. Jung,et al.  Therapeutic outcomes of endoscopic papillectomy for ampullary neoplasms: retrospective analysis of a multicenter study , 2017, BMC Gastroenterology.

[63]  M. Choti,et al.  Minimally Invasive Versus Open Pancreaticoduodenectomy: A Propensity-matched Study From a National Cohort of Patients , 2017, Annals of surgery.

[64]  M. Büchler,et al.  Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial , 2017, The Lancet.

[65]  D. Shibata,et al.  Management and outcomes following pancreaticoduodenectomy for ampullary adenocarcinoma. , 2017, American journal of surgery.

[66]  Jeffrey E. Lee,et al.  Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater , 2017, Annals of Surgical Oncology.

[67]  Z. Wang,et al.  A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer , 2016, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[68]  M. Reni,et al.  Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer , 2016, British Journal of Cancer.

[69]  S. Gill,et al.  PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  A. Krasinskas,et al.  Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases , 2016, Modern Pathology.

[71]  H. Jang,et al.  KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review , 2016, Oncotarget.

[72]  David Goldstein,et al.  Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. , 2016, JAMA.

[73]  M. Kwon,et al.  Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value. , 2016, Human pathology.

[74]  Jin‐Young Jang,et al.  Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer , 2016, PloS one.

[75]  Seung‐Mo Hong,et al.  Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma , 2016, Modern Pathology.

[76]  R. Higuchi,et al.  Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma. , 2016, Cancer cell.

[77]  Yan-Shen Shan,et al.  Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial , 2016, The Lancet.

[78]  R. Gibbs,et al.  Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. , 2016, Cell reports.

[79]  R. Salem,et al.  Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer , 2016, British Journal of Cancer.

[80]  W. Bernardo,et al.  Endoscopic versus surgical treatment of ampullary adenomas: a systematic review and meta-analysis , 2016, Clinics.

[81]  S. Kalloger,et al.  Immunophenotyping of ampullary carcinomata allows for stratification of treatment specific subgroups , 2015, Journal of Clinical Pathology.

[82]  G. Fontanini,et al.  FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. , 2015, The Lancet. Oncology.

[83]  V. Heinemann,et al.  Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater. , 2015, Surgery.

[84]  Kyubo Kim,et al.  Survival Benefit of Adjuvant Chemoradiotherapy in Patients With Ampulla of Vater Cancer: A Systematic Review and Meta-analysis. , 2015, Annals of surgery.

[85]  A. Maitra,et al.  Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma , 2015, British Journal of Cancer.

[86]  L. Borsu,et al.  Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2) , 2015, Modern Pathology.

[87]  C. Yang,et al.  Long-term prognosis of surgical treatment for early ampullary cancers and implications for local ampullectomy , 2015, BMC Surgery.

[88]  A. Krasinskas,et al.  Substaging Nodal Status in Ampullary Carcinomas has Significant Prognostic Value: Proposed Revised Staging Based on an Analysis of 313 Well-Characterized Cases , 2015, Annals of Surgical Oncology.

[89]  T. V. van Gulik,et al.  Impact of lymph node ratio on survival in patients with pancreatic and periampullary cancer , 2015, The British journal of surgery.

[90]  M. Al-Haddad,et al.  Performance characteristics of EUS for locoregional evaluation of ampullary lesions. , 2015, Gastrointestinal endoscopy.

[91]  K. Lillemoe,et al.  Survival in ampullary cancer: potential role of different KRAS mutations. , 2015, Surgery.

[92]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[93]  Laura H. Tang,et al.  The Utility of Immunohistochemistry in Subtyping Adenocarcinoma of the Ampulla of Vater , 2014, The American journal of surgical pathology.

[94]  F. Que,et al.  Adenomas of the Ampulla of Vater: A comparison of Outcomes of Operative and Endoscopic Resections , 2014, Journal of Gastrointestinal Surgery.

[95]  M. Kornmann,et al.  Survival and prognostic factors in pancreatic and ampullary cancer. , 2014, Anticancer research.

[96]  G. Puhl,et al.  Prognostic Factors for Long-Term Survival in Patients with Ampullary Carcinoma: The Results of a 15-Year Observation Period after Pancreaticoduodenectomy , 2014, HPB surgery : a world journal of hepatic, pancreatic and biliary surgery.

[97]  Y. Igarashi,et al.  Endosonographic Preoperative Evaluation for Tumors of the Ampulla of Vater Using Endoscopic Ultrasonography and Intraductal Ultrasonography , 2014, Clinical endoscopy.

[98]  S. Sherman,et al.  Endoscopic papillectomy: risk factors for incomplete resection and recurrence during long-term follow-up. , 2014, Gastrointestinal endoscopy.

[99]  T. Ponchon,et al.  Endoscopic papillectomy for early ampullary tumors: long-term results from a large multicenter prospective study , 2014, Endoscopy.

[100]  Shin-E Wang,et al.  Longterm survival after pancreaticoduodenectomy for periampullary adenocarcinomas. , 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[101]  S. Connor,et al.  Review of the investigation and surgical management of resectable ampullary adenocarcinoma. , 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[102]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[103]  A. Hinke,et al.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. , 2013, JAMA.

[104]  N. Kumari,et al.  Intestinal and pancreatobiliary differentiation in periampullary carcinoma: the role of immunohistochemistry. , 2013, Human pathology.

[105]  D. Shin,et al.  Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. , 2013, The Lancet. Oncology.

[106]  A. Parikh,et al.  Epidermal Growth Factor Receptor Signaling Pathway is Frequently Altered in Ampullary Carcinoma at Protein and Genetic Levels , 2013, Modern Pathology.

[107]  C. Bassi,et al.  Adequacy of Lymph Node Retrieval for Ampullary Cancer and Its Association with Improved Staging and Survival , 2013, World Journal of Surgery.

[108]  J. K. Lee,et al.  Prediction of Carcinoma After Resection in Subjects With Ampullary Adenomas on Endoscopic Biopsy , 2013, Journal of clinical gastroenterology.

[109]  J. Kench,et al.  Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  A. Azmy,et al.  Oxaliplatin and Bolus-Modulated 5-Fluorouracil as a Second-Line Treatment for Advanced Pancreatic Cancer: Can Bolus Regimens Replace FOLFOX When Considered for Second Line? , 2013, ISRN oncology.

[111]  Dawn M. Emick,et al.  Endoscopic Versus Surgical Ampullectomy: An Algorithm to Treat Disease of the Ampulla of Vater , 2013, Annals of surgery.

[112]  O. Clausen,et al.  Reclassification of tumour origin in resected periampullary adenocarcinomas reveals underestimation of distal bile duct cancer. , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[113]  E. Raymond,et al.  FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. , 2012, World journal of gastroenterology.

[114]  M. Büchler,et al.  Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. , 2012, JAMA.

[115]  S. Barni,et al.  FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study , 2012, Cancer Chemotherapy and Pharmacology.

[116]  C. Willett,et al.  Carcinoma of the Ampulla of Vater: Patterns of Failure Following Resection and Benefit of Chemoradiotherapy , 2012, Annals of Surgical Oncology.

[117]  David Cella,et al.  Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  J. Cameron,et al.  Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital - Mayo Clinic collaborative study , 2011, Radiation oncology.

[119]  K. Almhanna,et al.  Predictors of clinical outcomes of resected ampullary adenocarcinoma: a single-institution experience. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[120]  T. Desser,et al.  Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. , 2011, International journal of radiation oncology, biology, physics.

[121]  B. Dörken,et al.  Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. , 2011, European journal of cancer.

[122]  K. Hatakeyama,et al.  Assessment of the Nodal Status in Ampullary Carcinoma: The Number of Positive Lymph Nodes Versus the Lymph Node Ratio , 2011, World Journal of Surgery.

[123]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[124]  C. Yeo,et al.  The Influence of Prognostic Factors and Adjuvant Chemoradiation on Survival After Pancreaticoduodenectomy for Ampullary Carcinoma , 2011, Journal of Gastrointestinal Surgery.

[125]  F. D. De Braud,et al.  Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  Y. Kawabata,et al.  Cytokeratin 20 (CK20) and apomucin 1 (MUC1) expression in ampullary carcinoma: Correlation with tumor progression and prognosis , 2010, Diagnostic pathology.

[127]  D. Cunningham,et al.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.

[128]  M. Choti,et al.  Clinicopathologic Analysis of Ampullary Neoplasms in 450 Patients: Implications for Surgical Strategy and Long-Term Prognosis , 2010, Journal of Gastrointestinal Surgery.

[129]  M. Bloomston,et al.  Predictors of Survival in Periampullary Cancers Following Pancreaticoduodenectomy , 2010, Annals of Surgical Oncology.

[130]  T. Gauler,et al.  Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ , 2010, Anti-cancer drugs.

[131]  G. Stamp,et al.  Survival analysis after pancreatic resection for ampullary and pancreatic head carcinoma: An analysis of clinicopathological factors , 2009, Journal of surgical oncology.

[132]  W. Scheithauer,et al.  Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  L. Traverso,et al.  Papillectomy for ampullary neoplasm: results of a single referral center over a 10-year period. , 2009, Gastrointestinal endoscopy.

[134]  D. Park,et al.  A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer , 2009, British Journal of Cancer.

[135]  A. Bellizzi,et al.  The assessment of specimens procured by endoscopic ampullectomy. , 2009, American journal of clinical pathology.

[136]  P. Sakai,et al.  Prospective evaluation of EUS versus CT scan for staging of ampullary cancer. , 2009, Gastrointestinal endoscopy.

[137]  J. Cameron,et al.  Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[138]  Po-Huang Lee,et al.  Is Blind Pancreaticoduodenectomy Justified for Patients with Ampullary Neoplasms? , 2009, Journal of Gastrointestinal Surgery.

[139]  Jeffrey S. Morris,et al.  Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[140]  A. Novarino,et al.  Oxaliplatin, 5-Fluorouracil, and Leucovorin as Second-Line Treatment for Advanced Pancreatic Cancer , 2009, American journal of clinical oncology.

[141]  Chien-Hua Chen,et al.  Reappraisal of endosonography of ampullary tumors: Correlation with transabdominal sonography, CT, and MRI , 2009, Journal of clinical ultrasound : JCU.

[142]  Wei-xing Chen,et al.  Multiple imaging techniques in the diagnosis of ampullary carcinoma. , 2008, Hepatobiliary & pancreatic diseases international : HBPD INT.

[143]  K. Hess,et al.  Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer , 2008, Cancer.

[144]  Jeffrey E. Lee,et al.  Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  Jeffrey E. Lee,et al.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  O. Clausen,et al.  Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma , 2008, BMC Cancer.

[147]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[148]  C. Ko,et al.  Survival After Resection of Ampullary Carcinoma: A National Population-Based Study , 2008, Annals of Surgical Oncology.

[149]  S. Hochwald,et al.  Contemporary results with ampullectomy for 29 "benign" neoplasms of the ampulla. , 2008, Journal of the American College of Surgeons.

[150]  Douglas B. Evans,et al.  Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. , 2008, International journal of radiation oncology, biology, physics.

[151]  C. Fuchs,et al.  Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[152]  N. Fujita,et al.  Preoperative evaluation of ampullary neoplasm with EUS and transpapillary intraductal US: a prospective and histopathologically controlled study. , 2007, Gastrointestinal endoscopy.

[153]  Jin‐Young Jang,et al.  Recurrence and Prognostic Factors of Ampullary Carcinoma after Radical Resection: Comparison with Distal Extrahepatic Cholangiocarcinoma , 2007, Annals of Surgical Oncology.

[154]  L. Crinò,et al.  Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[155]  D. Stocken,et al.  A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin , 2007, Annals of Surgical Oncology.

[156]  D. Yoon,et al.  Factors influencing recurrence after curative resection for ampulla of vater carcinoma , 2007, Journal of surgical oncology.

[157]  Y. Shan,et al.  Predictors for Patterns of Failure after Pancreaticoduodenectomy in Ampullary Cancer , 2006, Annals of Surgical Oncology.

[158]  J. Donohue,et al.  Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. , 2006, International journal of radiation oncology, biology, physics.

[159]  V. Kapoor,et al.  Long-term Survival and Recurrence Patterns in Ampullary Cancer , 2006, Pancreas.

[160]  S. Choi,et al.  Can endoscopic resection be applied for early stage ampulla of Vater cancer? , 2006, Gastrointestinal Endoscopy.

[161]  J. Yeh,et al.  Limitations of Ampullectomy in the Treatment of Nonfamilial Ampullary Neoplasms , 2005, Annals of Surgical Oncology.

[162]  N. Soehendra,et al.  Endoscopic resection of benign tumors of the duodenal papilla without and with intraductal growth. , 2005, Gastrointestinal endoscopy.

[163]  E. Felekouras,et al.  Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study , 2005, Investigational New Drugs.

[164]  Markus Abt,et al.  Capecitabine as adjuvant treatment for stage III colon cancer. , 2005, The New England journal of medicine.

[165]  M. Shoup,et al.  Pancreaticoduodenectomy is curative in the majority of patients with node-negative ampullary cancer. , 2005, Archives of surgery.

[166]  F. Rotondi,et al.  Pancreatoduodenectomy for Tumors of Vater’s Ampulla: Report on 94 Consecutive Patients , 2005, World Journal of Surgery.

[167]  Abnish Kumar,et al.  Adjuvant chemo-radiotherapy in ampullary cancers. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[168]  R. Parks,et al.  Presentation, treatment and outcome in patients with ampullary tumours , 2004, The British journal of surgery.

[169]  S. Sherman,et al.  Endoscopic snare papillectomy for tumors of the duodenal papillae. , 2004, Gastrointestinal endoscopy.

[170]  J. Buckels,et al.  Favourable Prognostic Factors in a Large UK Experience of Adenocarcinoma of the Head of the Pancreas and Periampullary Region , 2004, Digestive Surgery.

[171]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[172]  Helen Hickey,et al.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.

[173]  M. Catalano,et al.  Endoscopic management of adenoma of the major duodenal papilla. , 2004, Gastrointestinal endoscopy.

[174]  C. Ko,et al.  Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections. , 2003, Archives of surgery.

[175]  J. Berlin,et al.  Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[176]  F. Borda,et al.  How accurate is preoperative diagnosis by endoscopic biopsies in ampullary tumours? , 2002, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[177]  G. Alexandrakis,et al.  Is endosonography an effective method for detection and local staging of the ampullary carcinoma? A prospective study , 2002, BMC surgery.

[178]  E. Van Cutsem,et al.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[179]  L. Mo,et al.  The accuracy of endoscopic ultrasound, endoscopic retrograde cholangiopancreatography, computed tomography, and transabdominal ultrasound in the detection and staging of primary ampullary tumors. , 2001, Hepato-gastroenterology.

[180]  A. Scarpa,et al.  Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis , 2001, British Journal of Cancer.

[181]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[182]  D. Tyler,et al.  Local ampullary resection with careful intraoperative frozen section evaluation for presumed benign ampullary neoplasms. , 2000, Surgery.

[183]  J. Jeekel,et al.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. , 1999, Annals of surgery.

[184]  C. Poremba,et al.  Tumors of the papilla of Vater--inadequate diagnostic impact of endoscopic forceps biopsies taken prior to and following sphincterotomy. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[185]  J. Lotz,et al.  CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. , 1999, European journal of cancer.

[186]  E. Rosato,et al.  EUS compared with CT, magnetic resonance imaging, and angiography and the influence of biliary stenting on staging accuracy of ampullary neoplasms. , 1999, Gastrointestinal endoscopy.

[187]  T. Mattfeldt,et al.  Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. , 1999, Archives of surgery.

[188]  G. Beck,et al.  The natural history of untreated duodenal and ampullary adenomas in patients with familial adenomatous polyposis followed in an endoscopic surveillance program. , 1999, Gastrointestinal endoscopy.

[189]  R. Labianca,et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.

[190]  G. Capellá,et al.  Cancers of the papilla of vater: mutator phenotype is associated with good prognosis. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[191]  A. Scarpa,et al.  APC gene mutations and allelic losses in sporadic ampullary tumours: Evidence of genetic difference from tumours associated with familial adenomatous polyposis , 1996, International journal of cancer.

[192]  D. Rattner,et al.  Defining the criteria for local resection of ampullary neoplasms. , 1996, Archives of surgery.

[193]  T. V. van Gulik,et al.  Results of pancreaticoduodenectomy for ampullary carcinoma and analysis of prognostic factors for survival. , 1995, Surgery.

[194]  T. Muto,et al.  Different Clinicopathologic Findings in Two Histologic Types of Carcinoma of Papilla of Vater , 1994, Japanese journal of cancer research : Gann.

[195]  Eric A. Swanson,et al.  Association of Histopathologic Phenotype of Periampullary Adenocarcinomas With Survival , 2017, JAMA surgery.

[196]  P. Senthilnathan,et al.  Long-term results of laparoscopic pancreaticoduodenectomy for pancreatic and periampullary cancer-experience of 130 cases from a tertiary-care center in South India. , 2015, Journal of laparoendoscopic & advanced surgical techniques. Part A.

[197]  M. Makary,et al.  2564 resected periampullary adenocarcinomas at a single institution: trends over three decades. , 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[198]  T. Bekaii-Saab,et al.  Ampullary cancer: an overview. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[199]  W. Regine,et al.  Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. , 2011, International journal of radiation oncology, biology, physics.

[200]  G. Elek,et al.  Histological evaluation of preoperative biopsies from ampulla Vateri , 2009, Pathology Oncology Research.

[201]  Yinmo Yang,et al.  Carcinoma of the Ampulla of Vater: Factors Influencing Long-term Survival of 127 Patients with Resection , 2006, World Journal of Surgery.

[202]  N. Ohkohchi,et al.  Patterns and Predictors of Failure after Curative Resections of Carcinoma of the Ampulla of Vater , 2003, Annals of Surgical Oncology.

[203]  M. Stolte,et al.  Adenoma-carcinoma sequence in the papilla of Vater. , 1996, Scandinavian journal of gastroenterology.